Loading clinical trials...
Loading clinical trials...
An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency
Conditions
Interventions
AG-348
Locations
19
United States
UCSF Benioff Children's Hospital
Oakland, California, United States
Emory University
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Toronto General Hospital, University Health Network
Toronto, Canada
University of Copenhagen, Herlev Hospital
Herlev, Denmark
Start Date
June 26, 2018
Primary Completion Date
November 12, 2020
Completion Date
November 12, 2020
Last Updated
January 4, 2022
NCT04170348
NCT06422351
NCT04964323
NCT03548220
NCT00749112
Lead Sponsor
Agios Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions